The purpose of the this study is to evaluate the clinical outcome of VEGFR-TKIs interruption in patients with metastatic renal cell carcinoma (mRCC) after achieving stable disease (SD) or better response.
Tumors continuously evolve to maintain growth; secondary mutations facilitate this process, resulting in high tumor heterogeneity. In this study, we compared mutations in paired primary and metastatic colorectal cancer tumor samples to determine whether tumor heterogeneity can predict tumor metastasis.
Docetaxel-based chemotherapy led to significant improvement in progression-free (PFS) and overall survival for patients with resectable gastric or gastroesophageal juncture (GEJ) cancer, according to a study reported at the European Society for Medical Oncology conference in Madrid.
Although there are several types of ovarian cancer, high-grade serous ovarian carcinomas are the most common. These cancers carry a poor prognosis and have historically been thought of as originating from the ovarian surface epithelium. However, several recent reports have raised the possibility that the fallopian tube epithelium is the actual origin of this deadly cancer, yet definitive evidence was lacking.
Evaluation of patients with advanced cancers by a virtual tumor board in precision oncology matched most patients with clinical trials and substantially reduced the cost of care, according to a small pilot study.
Drug development in oncology continues to experience high failure rate. We now understand that tumors are heterogeneous and dynamic, and we are seeing the importance of stratifying patients as well as continuously monitoring for resistant mutations. These measures may improve response rates to targeted therapies and their survival benefit.
Sinomenine (SIN), an isoquinoline isolated from the Chinese medicinal plant Sinomenium acutum, is well known for its curative effect on rheumatic and arthritic diseases. Recently, SIN has been reported to possess potent anti-tumor effects in various types of cancers. However, the role and the underlying mechanism of the inhibitory action of SIN on ovarian cancer remain unknown.
The FDA approved the chimeric antigen receptor (CAR) T-cell agent axicabtagene ciloleucel (axi-cel, Yescarta) for adults with certain types of relapsed or refractory large B-cell lymphoma. (MedPage Today)